KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Consolidated Net Income (2016 - 2026)

Biogen has reported Consolidated Net Income over the past 18 years, most recently at $319.5 million for Q1 2026.

  • For Q1 2026, Consolidated Net Income rose 32.85% year-over-year to $319.5 million; the TTM value through Mar 2026 reached $1.4 billion, down 7.26%, while the annual FY2025 figure was $1.3 billion, 20.79% down from the prior year.
  • Consolidated Net Income for Q1 2026 was $319.5 million at Biogen, up from -$48.9 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $1.1 billion in Q3 2022 and troughed at -$68.3 million in Q3 2023.
  • A 5-year average of $433.2 million and a median of $388.5 million in 2024 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: surged 1538.48% in 2022 and later tumbled 118.34% in 2025.
  • Year by year, Consolidated Net Income stood at $549.5 million in 2022, then plummeted by 54.7% to $248.9 million in 2023, then grew by 7.15% to $266.7 million in 2024, then tumbled by 118.34% to -$48.9 million in 2025, then skyrocketed by 753.37% to $319.5 million in 2026.
  • Business Quant data shows Consolidated Net Income for BIIB at $319.5 million in Q1 2026, -$48.9 million in Q4 2025, and $466.5 million in Q3 2025.